RxDoctor Payments Data

Kimberly Drouineaud, NP

Nurse Practitioner · Los Angeles, CANPI 1619629607

Payments from drug & device makers

$5,069in general payments, 2019–2025

Across 46 payments — averaging $110.20 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Impulse Dynamics (USA) Inc.$2K
  • Cvrx, Inc.$2K
  • E.r. Squibb & Sons, L.L.C.$255
  • Abbott$183
  • Alnylam Pharmaceuticals Inc.$150
  • AstraZeneca$148
  • plus $317 from 6 others

What the payments were for

  • Travel & lodging$2,31446%
  • Food & beverage$2,75554%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$5,069 in reported general payments places this provider in the 95th percentile of 6,779 nurse practitioner providers in California.

See all nurse practitioner providers in California

Medicare billing

Part B allowed, 2024
$18,716
Medicare patients
106
Services billed
191

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
VyndamaxTafamidis23$704,599
EntrestoSacubitril/Valsartan172$192,750
JardianceEmpagliflozin124$121,118
FarxigaDapagliflozin Propanediol131$106,218
EliquisApixaban45$53,320
LokelmaSodium Zirconium Cyclosilicate45$28,153
TrulicityDulaglutide14$17,567
XareltoRivaroxaban21$15,977
KerendiaFinerenone16$10,165
Eplerenone37$3,368
Bumetanide44$3,279
Metoprolol Succinate182$2,669
Midodrine Hcl42$2,544
Spironolactone181$1,310
Torsemide56$1,161

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
NovartisEntresto$94$192,750172 claims
AstraZenecaFarxiga, Lokelma$148$134,371176 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 6,779 nurse practitioner providers in California.

Other nurse practitioner in Los Angeles

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →